Loading...

Italian health companies eye potential in China

Image

03-Feb-16 Italy's medical device companies are looking at the development potential in China, one of the markets where Italy's exports of medical devices have increased the most - by 24% in 2014 - with an export value of EUR310 mn (USD430 mn). Italian companies already present in China include DiaSorin, a biotech group specialized in in-vitro diagnostics. [image: Ambasciata d'Italia Pechino]

Read More

China’s diabetes boom promises UD23 bn pot for drug makers

Image

30-Jan-16 How big is the potential market for diabetes drugs in China? As big as the entire populations of Australia, Canada and Argentina combined. And it's growing. Only about half of China’s diabetics have been diagnosed, and only 15% of those diagnosed are receiving comprehensive treatment, said Jakob Riis, head of China at Novo Nordisk, the world’s largest insulin maker. [image: AFP / Getty Images]

Read More

12 Healthcare growth markets stories from 2015, month-by-month

Image

18-Jan-16 As the healthcare industry considers the possibilities - and challenges - of the year ahead, here's a look back at 12 notable Healthcare growth markets stories from 2015 you may have missed, month-by-month, including "China’s physicians encouraged to take up second jobs", "Vietnam achieves healthcare Millennium Development Goals", "World's biggest healthcare facility financed in Turkey" and more.

Read More

China to open 20 overseas TCM centers

Image

21-Jan-16 China plans to open 20 Traditional Chinese Medicine (TCM) collaboration centers overseas in 2016. The centers will be based on the various needs for TCM in different countries and will require local partners, including hospitals, research institutions and pharma companies. The international market for TCM is valued at USD50 bn. [image: Bao Kangxuan / Asianewsphoto]

Read More

Challenges in mHealth clinical trials integration

Image

19-Jan-16 Currently, there is no global standard for mHealth in clinical trials, and the use of wearable devices raise regulatory challenges as sponsors question whether regulatory agencies in Asia and globally will accept mHealth data. Of particular concern are the expectations around safety monitoring. [image: BioSpectrum]

Read More
Share